Konference: 2007 3. ročník Dny diagnostické, prediktivní a experimentální onkologie
Kategorie:
Nádorová biologie/imunologie/genetika a buněčná terapie
Téma: Postery
Číslo abstraktu: 015p
Autoři: M. Sivoňová; RNDr. Tatiana Matáková, Ph.D.; Prof. MUDr. Dušan Dobrota, CSc.; doc. RNDr. Jozef Hatok, Ph.D.; M. Franeková; R. Kirschnerova; MUDr. Ján Kliment jr., PhD.; R. Tomaškin
Prostate-specific antigen (PSA) gene expression is regulated by
androgen receptor (AR) through androgen response elements (AREs) in
the promoter region of the PSA gene. A single nucleotide
polymorphism with guanine (G) to adenine (A) substitution is
identified at position -158 in the ARE of the PSA gene. Previous
studies suggest that this polymorphism may be associated with
higher PSA levels and increase prostate cancer risk. Detoxification
enzymes glutathione-S-transferases (GSTs) may play a role in the
formation of prostate cancer. GSTP1 has a polymorphic site at codon
105 (exon 5), where an adenosine-to-guanosine (A-G) transition
causes an Ile-to-Val substitution (Ile105Val) and produces a
variant enzyme with lower activity and less capability of effective
detoxification. The absence of GSTM1 activity is caused by
inheritance of two null alleles (alleles that have a deletion of
the GSTM1 gene) similarly; individuals with no GSTT1 activity also
have inherited null alleles of the GSTT1 gene, which lead to
absence of activity of these enzymes. We have investigated the
potential functional significance of these polymorphisms and its
association with prostate cancer susceptibility in 145 men
diagnosed with prostate cancer and 219 healthy control men. PSA and
GSTs polymorphisms were determined by poly-merase chain
reaction-based methods using DNA from peripheral blood samples. We
did not find a significant association between PSA polymorphism at
position – 158 and prostate cancer risk. The OR, calculated
relative to subjects with the A/A genotype, was for the A/G
genotype 0.95 (95% CL 0.56–1.6, and for the G/G genotype 0.62 (95%
CL 0.34–1.12), respectively. We observed non-significant
association in null alleles of the GSTM1 (OR = 0.92; 95% CI =
0.59-1.42 and GSTT1 (OR = 0.62, 95% CI = 0.35-1.08) with risk of
bladder cancer. Prostate cancer risk was moderately increased with
the GSTP1(Val/Val) genotype (OR = 1.46; 95% CI 1.46-4.55). Our
findings suggest that GSTP1(Val/Val) genotype may affect the risk
of prostate cancer and tumor aggressiveness. Further, GSTM1 null,
GSTT1 null genotypes did not appear to influence the susceptibility
to prostate cancer.
This work was supported by grants UK/264/2006, MVTS Bil/
ČR/SR/UK/06 and AV 4/0013/05.
Datum přednesení příspěvku: 28. 11. 2007